These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 9895443)
21. Adsorption dialysis: from physical principles to clinical applications. Aucella F; Gesuete A; Vigilante M; Prencipe M Blood Purif; 2013; 35 Suppl 2():42-7. PubMed ID: 23676835 [TBL] [Abstract][Full Text] [Related]
22. Behaviour of clearances and diffusive permeability during hemodialysis with PMMA dialyzers: clinical study. Ghezzi PM; Canepari G; Ronco C Contrib Nephrol; 1999; 125():53-64. PubMed ID: 9895430 [No Abstract] [Full Text] [Related]
23. Beta-2-microglobulin amyloidosis in uremic dialyzed patients. Brancaccio D; Gallieni M; Padovese P; Anelli A Contrib Nephrol; 1989; 70():202-7. PubMed ID: 2670429 [No Abstract] [Full Text] [Related]
24. Towards long-term dialysis: a personal view. Davison AM Artif Organs; 1999 Jan; 23(1):6-9. PubMed ID: 9950172 [No Abstract] [Full Text] [Related]
25. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Schiffl H; Fischer R; Lang SM; Mangel E Nephrol Dial Transplant; 2000 Jun; 15(6):840-5. PubMed ID: 10831638 [TBL] [Abstract][Full Text] [Related]
26. Are biocompatible membranes superior for hemodialysis therapy? van Ypersele de Strihou C Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694 [No Abstract] [Full Text] [Related]
27. Erosive osteoarthropathy associated with beta 2-microglobulin amyloidosis in a uraemic patient treated exclusively by long-term haemofiltration with biocompatible membranes. Renaud H; Fournier A; Moriniere P; Westeel PF; el Esper N; Belbrik S; Marie A; Cohen-Solal HE; Sebert JL Nephrol Dial Transplant; 1988; 3(6):820-2. PubMed ID: 3147427 [No Abstract] [Full Text] [Related]
28. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Randoux C; Gillery P; Georges N; Lavaud S; Chanard J Kidney Int; 2001 Oct; 60(4):1571-7. PubMed ID: 11576375 [TBL] [Abstract][Full Text] [Related]
29. Kinetics of 131I-beta2 microglobulin in hemodialysis patients: assessment using total body counting. Chanard J; Caudwell V; Valeire J; Vincent C; Randoux C; Wuillai A; Wynckel A Artif Organs; 1998 Jul; 22(7):574-80. PubMed ID: 9684694 [TBL] [Abstract][Full Text] [Related]
30. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes. Floege J; Koch KM Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985 [No Abstract] [Full Text] [Related]
34. Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high- or low-flux dialyzer membranes? Haufe CC; Eismann U; Deppisch RM; Stein G Kidney Int Suppl; 2001 Feb; 78():S177-81. PubMed ID: 11169006 [TBL] [Abstract][Full Text] [Related]
35. Are there long-term clinical consequences related to membrane biocompatibility? van Ypersele de Strihou C; De Meyer M Contrib Nephrol; 1989; 71():36-9. PubMed ID: 2680264 [No Abstract] [Full Text] [Related]
36. Can the nephrologist prevent dialysis-related amyloidosis? Zingraff J; Drüeke T Am J Kidney Dis; 1991 Jul; 18(1):1-11. PubMed ID: 2063840 [TBL] [Abstract][Full Text] [Related]
37. Long-term variations of serum beta 2-microglobulin levels in hemodialysed uremics according to permeability and bioincompatibility of dialysis membranes. Simon P; Cavarle YY; Ang KS; Cam G; Catheline M Blood Purif; 1988; 6(2):111-6. PubMed ID: 3293614 [TBL] [Abstract][Full Text] [Related]